Panel discussion
Date:April 22, 2024

Panel title

Investments into global HC systems

Panel summary

HC investments in low- and middle-income countries are engines of economic growth, social equity, and political stability. The Swiss life sciences industry, together with Swiss government organizations, academic institutions, and Swiss-based non-profit organizations, plays a key role in HC programs around the world. To further maximize the ROI of HC spending in LMICs, a more synchronized approach among Swiss stakeholders is needed.

Speaker information


André Guedel, President Swiss African Business Circle, Head BD KPMG


Dr. Lutz Hegemann President, Global Health & Sustainability, Novartis
Michael Altorfer, CEO, Swiss Biotech Association
Dr. Jörg Schläpfer, Head Intl. Relations, Swissmedic
Sitara Merchant, CEO, Swiss Capacity Building Facility (SCBF)


Company profile

KPMG is a leading professional services firm in Switzerland, noted for clear and consistent solutions in audit, tax and advisory. Through its strong regional presence KPMG is close to you, helping you navigate today’s turbulences to find tomorrow’s answers.. KPMG’s Life Sciences experts have a deep understanding of the industry to support companies in challenges around cost & efficiency, valuation & financing or regulatory compliance.